 |
De Facto
has acquired MC Bio-Communications, a specialist life science investor
relations company, adding a valuable new resource for clients. Simultaneously,
our parent, the Bell Pottinger Group has formed Bell Pottinger Health,
a new business dedicated to leading the expansion of its health franchise.
The new agency, which will work in conjunction with De Facto, is in
the process of establishing an international footprint, reflecting
the global needs of clients in the pharmaceutical sector. Read more> |
 Flow cytometry software leader chooses De Facto |
 |
 Effective patient recruitment |
 Royal Society, 2 – 6 pm, 20 May 2008 |
|
 Interactive webcast now viewable online |
| “I
am impressed by the speed De Facto responded to my brief and created
opportunities for us to showcase our technology. They are living
up to their reputation for generating powerful editorial coverage
in the trade journals that really matter.” Neil Butler, CEO, Vivacta |
 |
“Thanks again to you for the excellent job you
did helping to promote BioTrinity. I consider De Facto's activities
a crucial part of the overall success of BioTrinity 2007, which was
judged by as "excellent or good" by 91% of evaluation responders.” Dr. Jon Rees, Director, Oxfordshire Bioscience Network |
Ofir Neuman, Marketing Director, Aesthera |
||
 |
 |
 |
 |
 |
Healthcare |
Life Science |
Clinical Trials Marketing |
Medical Education |
Design |
Find out more about
the full range of services we provide to leading pharmaceutical
and healthcare companies
and healthcare companies